- Trial phase
- Phase 2
- Time to market
- FT819 is in Phase 2 testing (RECLAIM-LN, a potentially registrational trial) that began enrolling in August 2026. If successful, an FDA submission could be several years away, likely in 2028-2029 at the earliest.
- Why 4/10
- FT819 is in Phase 2 (RECLAIM-LN) with the first patient dosed in August 2026. The next hard catalyst is interim Phase 2 data expected in H2 2027, which is more than 12 months away. No PDUFA or pivotal readout is scheduled within the next 12 months, capping the impact score at 4.
The next major catalyst for FT819 is the Phase 2 RECLAIM-LN interim data expected in H2 2027. Positive data would validate the registrational trial and could drive significant upside for this single-asset-focused biotech. Negative or mixed data would be bearish. The stock trades at $1.26 with a 52-week range of $0.95-3.23. The newly effective $100M ATM facility signals potential near-term dilution risk.
Price Chart
Executive Summary
FT819 is an off-the-shelf, iPSC-derived CD19-targeted CAR T-cell therapy developed by Fate Therapeutics (NASDAQ: FATE). It is being developed primarily for autoimmune indications including lupus nephritis and systemic sclerosis. Phase 1 data presented at ACR Convergence 2026 showed 36 patients treated across three regimens and four autoimmune indications with no dose-limiting toxicities. A Phase 2 potentially registrational trial (RECLAIM-LN) started in August 2026 with the first patient dosed, and the company received a $15M CIRM CLIN2 grant. The stock trades at $1.26, with a 52-week range of 0.95-3.23. A $100M ATM facility was filed on November 12, 2026, enabling up to $100M in potential equity issuance. Analyst consensus is bullish with a mean price target of $5.72 (327% upside) but the next hard catalyst is over 12 months away.
How It Works
FT819 is an off-the-shelf CAR T-cell therapy made from induced pluripotent stem cells (iPSCs). It is engineered to target CD19, a protein found on the surface of B cells. In autoimmune diseases like lupus, the body's own B cells mistakenly attack healthy tissue. FT819 is designed to seek out and destroy these problematic B cells, potentially resetting the immune system. Because it is made from a master cell bank rather than each patient's own cells, it can be manufactured in large batches and given to any patient without the weeks-long personalized manufacturing process required by traditional CAR-T therapies.
Trial Status
FT819 has completed Phase 1 testing (FT819-102) in autoimmune diseases with data presented at multiple medical conferences in 2025-2026. A Phase 2 potentially registrational trial (RECLAIM-LN, FT819-201, NCT07570862) in lupus nephritis began in August 2026 with the first patient dosed. The company plans to open 20 trial sites by end of 2026 and expects interim analysis data in H2 2027.
The Two-Sided Case
Upcoming Catalysts
- Interim Phase 2 RECLAIM-LN data expected in H2 2027
- Additional data presentations at medical conferences in 2027
- Potential updates on FT839 (next-generation candidate)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
FATE THERAPEUTICS INC 424B5 FATE ·Originating report